Abstract
Study objective: Our objective was to determine if bamlanivimab (LY-CoV555; BAM), a monoclonal antibody for mild-to-moderate Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2, prevented emergency department (ED) visits, hospitalizations for SARS-CoV-2, or death within 60 days of a positive SARS-CoV-2 viral test.
Design: Patient propensity matching was performed for BAM administration to get two discrete groups of patients; those who received BAM (N = 117) and those who did not (N = 117).
Setting: Outpatients (N = 2107) eligible to receive BAM from November 1 to December 31, 2020, were identified.
Patients: A total of 144 of 2107 patients with mild-to-moderate SARS-CoV-2 received BAM INTERVENTION: Eligible patients had mild-to-moderate SARS-CoV-2 disease, a positive SARS-CoV-2 test, and risk factor(s) for progression to severe SARS-CoV-2 infection. All patients were reviewed for subsequent ED visits, subsequent hospitalization, and death.
Measurements and main results: Patients (N = 234) were matched, 117 in each group. Median (interquartile range) age was 72 (65-80) years. Forty-seven percent of patients were male. Twenty-one patients who received BAM were subsequently seen in the ED compared to 34 untreated patients (18.0% vs. 29.1%; p = 0.045). Fourteen BAM-treated patients were subsequently hospitalized post-BAM infusion compared to 27 untreated patients (12.0% vs. 23.1%; p = 0.025). Finally, there were no mortalities in the BAM group, however, eleven patients in the untreated group died (0.0% vs. 9.4%; p < 0.001). The number needed to treat (NNT) is 11 patients to prevent one mortality event.
Conclusions: BAM infusion for mild-to-moderate SARS-CoV-2 infection in outpatients significantly prevented subsequent ED visits, hospitalizations, and death from SARS-CoV-2.
Keywords: Bamlanivimab; SARS-CoV-2 infection; emergency room; hospitalization; mortality.
【저자키워드】 Hospitalization, SARS-COV-2 infection, bamlanivimab, mortality., emergency room, 【초록키워드】 severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, coronavirus, Hospitalized, Mortality, SARS-COV-2 infection, monoclonal antibody, Infection, risk, progression, coronavirus 2, bamlanivimab, emergency department, Viral, hospitalizations, male, Patient, death, age, outpatients, respiratory, group, LY-CoV555, emergency room, Outpatient, infusion, administration, Mild-to-moderate, interquartile range, SARS-CoV-2 disease, acute respiratory syndrome, Eligible patients, severe SARS, treat, positive, SARS-CoV-2 test, SARS-Co, mortalities, measurement, Prevent, severe SARS-CoV-2, SARS-CoV-2 viral, died, significantly, subsequent, was performed, determine, prevented, receive, BAM, eligible, NNT, untreated patient, 【제목키워드】 COVID-19, Cohort, Mild-to-moderate,